School of Food Science and Nutrition, University of Leeds, Leeds, LS2 9JT, United Kingdom.
Department of Food Science and Technology, Universitas Trilogi, Jakarta, 12760, Indonesia.
Food Funct. 2024 Apr 22;15(8):3959-3979. doi: 10.1039/d3fo04195f.
The majority of known peptides with high bioactivity (BAPs) such as antihypertensive, antidiabetic, antioxidant, hypocholesterolemic, anti-inflammatory and antimicrobial actions, are short-chain sequences of less than ten amino acids. These short-chain BAPs of varying natural and synthetic origin must be bioaccessible to be capable of being adsorbed systemically upon oral administration to show their full range of bioactivity. However, in general, and studies have shown that gastrointestinal digestion reduces BAPs bioactivity unless they are protected from degradation by encapsulation. This review gives a critical analysis of short-chain BAP encapsulation and performance with regard to the oral delivery route. In particular, it focuses on short-chain BAPs with antihypertensive and antidiabetic activity and encapsulation methods nanoparticles and microparticles. Also addressed are the different wall materials used to form these particles and their associated payloads and release kinetics, along with the current challenges and a perspective of the future applications of these systems.
大多数具有高生物活性(BAPs)的已知肽,如降压、抗糖尿病、抗氧化、降胆固醇、抗炎和抗菌作用,都是由不到十个氨基酸组成的短链序列。这些具有不同天然和合成来源的短链 BAP 必须具有生物可及性,才能在口服给药后被全身吸收,从而发挥其全部生物活性。然而,一般来说, 和 研究表明,胃肠道消化会降低 BAP 的生物活性,除非它们通过封装来防止降解。本综述对短链 BAP 的封装和性能进行了批判性分析,涉及口服递送途径。特别是,它重点关注具有降压和抗糖尿病活性的短链 BAP 及其封装方法 纳米粒和微球。还讨论了用于形成这些颗粒的不同壁材料及其相关的有效载荷和释放动力学,以及这些系统当前面临的挑战和未来应用的展望。